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Abstract
A considerable portion of patients with colorectal cancer have a high risk of disease recurrence after surgery. These patients
can be identified by analyzing the expression profiles of signature genes in tumors. But there is no consensus on which
genes should be used and the performance of specific set of signature genes varies greatly with different datasets,
impeding their implementation in the routine clinical application. Instead of using individual genes, here we identified
functional multi-gene modules with significant expression changes between recurrent and recurrence-free tumors, used
them as the signatures for predicting colorectal cancer recurrence in multiple datasets that were collected independently
and profiled on different microarray platforms. The multi-gene modules we identified have a significant enrichment of
known genes and biological processes relevant to cancer development, including genes from the chemokine pathway.
Most strikingly, they recruited a significant enrichment of somatic mutations found in colorectal cancer. These results
confirmed the functional relevance of these modules for colorectal cancer development. Further, these functional modules
from different datasets overlapped significantly. Finally, we demonstrated that, leveraging above information of these
modules, our module based classifier avoided arbitrary fitting the classifier function and screening the signatures using the
training data, and achieved more consistency in prognosis prediction across three independent datasets, which holds even
using very small training sets of tumors.
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Introduction
Colorectal cancer is one leading cause of cancer mortality.
About 20–30% of patients at stage II and 50% of patients at stage
III experience disease recurrence after surgery [1]. Accuracy and
stability of the prognosis prediction are critical when determining
the appropriate therapy scheme regarding different recurrence
risk. The recent studies have suggested the expression profile of
multi-gene signatures as a better prognosis predictor for patients
with colorectal cancer than traditional methods using clinical or
pathological features, and some are entering the market [2–7].
These signature genes were typically identified from differentially
expressed genes between a training set of tumors from patients
with or without disease recurrence. Their expression data were
then used to train a statistical classifier that can best discriminate
the two groups of training tumors. In some cases, these steps, i.e.
the gene selection and classifier construction, are iterated to
optimize both choices.
One major problem with these multi-gene classifiers is that their
signature genes vary significantly for different cohorts of studies,
different populations of patients, and different microarray
platforms, presumably due to the low accordance between
microarray expression data [8]. To get a consensus list of signature
genes, it is estimated that thousands of tumor samples would be
needed for training such classifiers [9]. As a result, the several
reported sets of signature genes highly depended on the training
samples and had only overlap minimally [10]. Another concern is
that the choice of a statistical classifier is arbitrary and lacks
explicit biological basis, so that the classifier may be over-fitted by
the dataset from which it was invented. For example, in one recent
study, the multi-gene classifiers constructed from one dataset were
cross-validated in a different dataset to find that their prediction
accuracy was substantially reduced [3]. Such reduction was due to
some missing genes in the gene classifier relative to the best
classifier constructed from the cross-validation dataset. Therefore,
these factors have led to high variability in the predictive
performance of multi-gene classifiers and limited their generalized
usage in clinical practice.
Recently, higher accordance across different microarray dataset
has been reported in the expression patterns of multi-gene
modules, i.e. groups of functionally related genes [11–14].
Motivated by this finding, we aimed to identify such modules by
combining both gene expression and protein interaction data and
used the most differentially expressed modules to construct a novel
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randomly associated with colorectal cancer recurrence in different
datasets, and that the modules from different datasets overlap by
significantly more genes than random, indicating the overlapping
percentage of the top ranked modules possessed discriminative
power. In this way, we avoided the use of the low-accordance gene
signatures and an arbitrary statistical function to fit. We
demonstrated its application to three independent datasets of
colorectal cancer patients that profiled on different microarray
platform and obtained reproducible predictions with accuracies of
74%, 76% and 68%, and AUC (area under ROC) values of 79%,
79% and 72% by Leave-One-Out validation. Reasonable
accuracies are seen when decreasing the size of training sets (34,
10 or 18 tumors) and the variability across datasets remains low,
which is ,1/2 of existing multi-gene based classifiers.
Materials and Methods
Data source
Tumor expression data and preprocessing. Three public
pre-processed microarray datasets of colorectal tumors as below
were used; note that the classification of the patients, recurrent or
non-recurrent, is referred to the actual status described in the
original papers or description files:
(1) German dataset [3]: It included 55 German patients with
primary colorectal cancer (stage I and II), where 29 patients
are disease recurrence free and their follow-up time at least
5.3 years after surgery. The expression of tumor samples was
profiled on the Affymetrix HG-U133A platform.
(2) Barrier dataset [5]: It included 50 patients with stage II
colorectal cancer. 25 of them are disease recurrence free and
their follow-up time at least 5 years after surgery. The
expression of tumor samples was profiled on the Affymetrix
HG-U133A platform.
(3) GSE5206 [15]: It included 100 patients with stage I–IV
colorectal cancer. 23 of them had disease recurrence after
surgery. There is no information about their follow up time.
Here we removed 37 samples with higher stage (III and IV)
from the recurrent-free sets and leaved 63 patients for
prediction validation. The expression of tumor samples was
profiled on the Affymetrix HG-U133_plus_2 platform.
For each probe with missing values, we applied R package
‘impute’ [16] to fill with the average of its k-nearest neighbors
Genes with multiple probes were processed by averaging their
expression level.
Gene ontology data. Gene ontology (GO) data from the
Molecular Signatures Database (MsigDB) v2.5 [17] were used,
which included 1454 GO sets and 8299 genes.
Protein interaction data. The protein interaction data were
downloaded from the HPRD database [18] (release 8) and
BioGRID the database [19], which included 6511 nodes and
29694 interactions.
Known genes related with colorectal cancer
recurrence. Colorectal cancer recurrence related genes were
collected based on their annotations from two sources,
respectively: OMIM database (www.ncbi.nlm.nih.gov/omim)
[20] and online literature mining using PubGene (http://www.
pubgene.org/) [21]. We obtained 41 related genes from OMIM
database. Using PubGene, we first searched for genes associated
with the term ‘colorectal cancer’ and ‘recurrence’ to obtain 2793
and 1609 genes, respectively, and then took the intersection of
these two gene lists as the final set of 1038 colorectal cancer
recurrence related genes.
Colorectal cancer somatic mutation data. The somatic
mutation data for colorectal cancer is downloaded from COSMIC
database [22] in the category of ‘the large intestine tissue’, not
including the sub-tissue, anus and appendix, with all two
histological terms: adenoma and carcinoma.
Constructing GO co-expression networks
We built networks for each GO gene set. This was for three
reasons: (1) it proved useful to incorporate prior information, e.g.
genes within the same pathways, to facilitate computational
methods in identification of functional modules [23–26]; (2) it
allows multi-functional genes to be present in more than one
functional modules; (3) many interaction data were obtained in-
vitro and may not exist in physiological situations and therefore,
limiting the interactions within a gene ontology may help reduce
such false positives. In details, for each GO gene set, genes not
present in the microarray dataset were removed. The remaining
genes in each GO set are used as vertices of the network and the
edges were drawn based on protein interaction data. Each vertex is
associated with an n-dimensional expression vector where n is the
total number of tumor samples in the dataset. The value at each
dimension is the expression level of this gene in the corresponding
tumor sample. The edge between any two vertices is weighted by
their co-expression level [27]. Here we chose the Pearson
correlation coefficient to measure the co-expression level. Note
that there are a few alternative metrics, e.g. Spearman correlation
and mutual information, and these metrics generally led to similar
results in network properties and module discovery [28].
Furthermore, Pearson correlation coefficient has been widely used
and suggested to be a good way to handle noises within the
microarray data [29,30], since it measures the collaborative degree
of two expression vectors but not the strength of them. Specifically,
the weight of an edge between two vertices i and j is defined as the
absolute value of person correlation coefficient between their
expression vectorsxi, xj:
Sij~ cor(Xi,Xj)
        ð1Þ
Identifying functional modules
There are several methods to identify modular structures within
a network and the choice of method varies with several factors, e.g.
the network structures [31]. Considering the dense structure of
each GO network, we applied the weighted Girvan and Newman
(GN) algorithm [32] for module discovery. Compared to other
existing methods that start with seed nodes and explore the vicinity
for high scored modular structures [11,33–36], the GN algorithm
is edge-oriented and search for globally optimal modules. It is
based on shortest-path algorithm, calculates the betweenness of all
edges and repeated removes the edge with highest betweenness.
Here, the betweenness score of an edge is defined by the sum of
the all shortest paths passing through it and divided by its weight of
corresponding edge. The original GN algorithm always cuts the
dendrogram at highest Q value, which results in a large variation
in the module size and sometimes huge modules with low
biological coherence [37]. To avoid this problem, we required
each module to contain no more than 20 genes. The detailed
procedures are as follows:
(1) Calculate betweenness scores of all edges in each GO
network.
Prognosis Prediction of Colorectal Cancer
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graph.
(3) Repeat above steps until no isolated graphs contain over 20
genes.
(4) Singletons with only one gene were ignored.
Rank differentially expressed modules between tumors
with and without recurrence
The expression changes between tumors with and without
recurrence were evaluated by our P-SAGE algorithm [38]. For a
module s with a total of k genes, the score of differential
significance (SDS) is defined by:
SDS(s)~
X k
i~1
Ti
2 ð2Þ
where Ti is the t score for i-th gene in the module s. Noticing that
the SDS scores correlates with the module size k, we obtained
their corresponding p-values from the chi square distribution
*x2(k), which are used to sort the identified functional modules
in ascending. Modules with higher rankings, i.e. the most
differentially expressed modules with smaller p-values, are used
for evaluation and prognosis prediction.
The prognosis prediction paradigm
The scheme of the prediction paradigm. Given a training
set of tumor samples, we split it into two halves, [R1] and [R2],
each with n non-recurrent and n-1 recurrent tumors. These two
halves are considered as two independent datasets. Then, we
assume the test tumor (i.e. unlabeled) X as recurrent and put it into
[R1] and [R2], i.e. [R1+X] and [R2+X]. We identified the top N
modules from [R1+X] and [R2+X], respectively, and if the test
tumor X is associated with high risk of recurrence, the two sets of
resultant modules should overlap substantially. We calculated the
overlapping percentage (OPN) which is calculated by the ratios of
their intersection and their union, after being normalized against
the overlapping percentage of corresponding modules identified
from [R1] and [R2]. To avoid potential bias with a specific split,
we repeated random split and above for 10 times to obtain an
average ,OPN.. Finally, we computed ,OPN. for different
N=100, 200… 500 and use the average as the predictive score
,OP.. Higher ,OP. score indicates a higher risk of recurrence
associated with the test tumor X. In this way, we avoid the
common strategy of optimizing an arbitrary kernel function that
has no clear biological basis.
Evaluation and comparison. For each dataset, its tumor
samples were divided into a training set and a test set. We reported
the performance measure, accuracy and AUC, with R package,
ROCR. In leave one out validation, one tumor was randomly
chosen as the test set and the rest tumors are used as the training set.
In this way, the prediction was conducted for n times, where n is the
total number of tumors in the dataset. In validations with the
number of training samples being 34, 18 or 10, we conducted the
prediction for (n-34),(n-18)or(n-10) times.Thenwe randomly chose
the training set of tumors for 5 times and reported the average,
maximal and minimal performance. The performance was
compared with other methods using these three microarray datasets.
Results
We used two independent datasets of early colorectal cancer
patients to verify the two key hypotheses: (1) the most differentially
expressed modules are non-randomly associated with tumor
recurrence; (2) such modules identified from different datasets
will overlap significantly in more genes than random.
Overview of most differentially expressed modules
identification
The identification of most differentially expressed modules
included three key steps: network construction, topological module
discovery, evaluation of differential expression at module level
(Figure 1, more detailed description in METHOD AND
MATRIERAL section). Briefly, we firstly clustered genes into
large groups based on their GO annotation. As a gene may have
more than one functional role, these GO groups may overlap in
certain genes. Instead of constructing a single giant network, we
used protein interaction data to build networks for each of these
GO set of genes and identified multi-genes modules, i.e. groups of
genes that are densely connected in network topology and
relatively separate from the rest network. Lastly, the differential
expression of each module between tumors with and without
disease recurrence was ranked to obtain the top N modules for
subsequent analysis.
The constructed GO networks contain 4428 genes in total for
both Barrier and German datasets as they used the same
microarray platform. We took the top 100, 200, …, 500 modules
for subsequent analysis (Table S1). These modules have a
differentially expressed p-value no greater than 0.005 in both
German dataset and Barrier dataset.
The most differentially expressed modules are non-
randomly associated with tumor recurrence
As can be seen in Figure 2, we found a significant enrichment of
genes related with colorectal cancer recurrence in these modules
identified from German dataset according to both OMIM and
PubGene annotations (see Methods). For control purposes, we
generated sets of a same amount of genes that are identified as the
most differentially expressed using the individual gene based t-test
(‘‘t-test genes’’), or the most differentially expressed GO gene sets
ranked by P-SAGE. Compared to these two controls, we found the
higher proportions of colorectal cancer recurrence related genes
were in the top 50–500 modules. They are about 1.9,3.5 times
(OMIM) and 2,2.7 times (PubGene) higher versus top ranked
individual genes, 2.6,4.7 times (OMIM) and 1.7,2.1(PubGene)
times higher versus top ranked GO gene sets (Figure 2). Similar
results were also seen for Barrier dataset (Figure S1).
Specifically, in analyzing the German dataset, we found three
chemokines (CXCL9, CXCL10 and CXCL11) and their shared
receptor CXCR3 in the top 10 modules. This is consistent with the
recent finding that CXCR3 and another ligand CXCL10 promote
invasion-related properties in colorectal cancer [39,40]. To see if
these results were reproducible, we randomly split German dataset
into two halves, each being a smaller dataset with 14 or 15 non-
recurrent tumors and 13 recurrent tumors, identified the top 100
modules and check if these chemokine related genes would show
up. We performed such random splits for 1000 times and counted
the frequencies of genes that appear at least once in both halves for
top 100 modules. Also, considering hub genes that have more
interacting partners would have a higher chance to show up in
more modules, we normalized the frequency of each gene against
its connectivity. We found the three chemokines: CXCL10,
CXCL9 and CXCL11, yet not their receptor CXCR3, appear the
most frequent (30.5%–44.1%) in all 1,000 splits. However, we
performed the same analysis on Barrier dataset and did not found
any of the three chemokines to show up in the top 100 modules in
Prognosis Prediction of Colorectal Cancer
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genes in the chemokine signaling pathway (190 genes in total) as
curated at KEGG database showed up at least once in top 100
modules in German dataset and Barrier dataset, respectively
(Table S2). They overlapped by 9 genes (STAT2, STAT3, LYN,
MAPK1, FOXO3, NFKB1, GSK3B, PAK1 and PTK2B). These
results indicate a possibility that the top modules were able to
capture substantial changes (10%) in the chemokine signaling
Figure 1. Schematic overview of most differentially expressed modules identification. Identifying the most differentially expressed
modules include three key steps. First, the GO co-expressed network is constructed by combined the protein-protein interaction network, which was
from the HPRD and BioGRID database, and GO gene sets together. The edges of network were weighed by co-expression level between their
corresponding linked nodes. Second, functional modules were identified by the weighted Girvan-Newman algorithm [32]. Finally, functional modules
were ranked on their differential levels between recurrent and non-recurrent tumors which were evaluated by the p-SAGE algorithm [38].
doi:10.1371/journal.pone.0033653.g001
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PLoS ONE | www.plosone.org 4 March 2012 | Volume 7 | Issue 3 | e33653Figure 2. The percentage of known colorectal cancer (CRC) genes in top 50–500 MDMs inferred from German dataset. Known CRC
genes were collected from the PubGene (A) or OMIM (B). The percentages were compared with those in top differentially expressed genes (t-test
genes) with the same number of genes in top ranked N modules, or GO gene sets with the same amount of top ranked N modules.
doi:10.1371/journal.pone.0033653.g002
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across different datasets. But it may be hard to further get down to
specific genes in these modules to use as robust markers.
As tumor develops with the accumulation of somatic mutations,
we also assessed if there is a significant correlation between the top
modules and the somatic mutations identified in colorectal cancer
from COSMIC database. We first identified the modules that
contain significant amount of mutations by Fisher exact test (p
cutoff: 0.05). These modules were named as Mutated Modules
(MMs). We then calculated percentages of MMs in top N modules
and the rest modules to obtain an enrichment ratio. A higher ratio
indicates a higher enrichment of mutations in the top N modules.
For German dataset, we found its top 50–500 modules overlap
significantly with MMs (Fisher exact test, p,0.002), with the
enrichment scores around 3–4 (Figure 3). In contrast, we
conducted a similar analysis on top genes of similar numbers
identified by the conventional t-test (‘‘t-test genes’’) but found no
significant overlap with genes in MMs (Fisher exact test, p-
values.0.25). The percentages of mutated genes in top t-test genes
vs. the rest genes are similar. To assess if the enrichment of
mutations in top modules are associated with tumor recurrence,
we permuted the labels of ‘‘recurrence’’ and ‘‘non-recurrence’’ to
identify the top modules and found their enrichment ratios are
about 1.3, which is comparable to those of the t-test genes. The
similar results were also found in Barrier dataset (FigureS2).
To this end, we confirmed our first assumption that the
identified top modules are non-randomly associated with tumor
recurrence in two different independent datasets. Therefore, these
modules may be used as more robust predictors than specific genes
for prognosis prediction.
The most differentially expressed modules had higher
reproducibility
Next, we examined if the overlapping percentages of top
modules are significantly higher than controls to be used as a
discriminative metric. We identified top 100–1000 modules from
Barrier and German datasets, respectively, and found these
modules from the two different datasets overlapped significantly
(p,1.75E-74). Their overlapping percentages (25.3%–54.9%) are
over 7 times higher than the overlapping percentages of top t-test
genes (3.3%–6.6%) and are also about 2 times of the mean
overlapping percentages for top modules identified after permut-
ing labels (Figure 4). Remarkably, these overlapping percentages
are also higher than the extreme values obtained in the
permutation cases, as outliers (Grubbs outlier test, p-val-
ues,0.006). Taken together, these results supported our second
assumption and suggested the overlapping percentages of top
modules are informative to predict tumor recurrence.
A novel classifier based on the most differentially
expressed modules can yield more robust prognosis
predictions
Given above validations of our two key assumptions, we
designed the prognosis prediction paradigm as follows. Briefly, we
split the training set of tumors into two different sets. Each set
contains both recurrent and non-recurrent tumors, so that the
corresponding top modules can be inferred. An overlapping
percentage (OP_old) of these modules from both sets was
computed. Given a test tumor, we assumed it is ‘‘recurrent’’ and
put it into each set to identify the new top modules and calculated
the new overlapping percentage (OP_new). If the test tumor is
‘‘recurrent’’ as expected, the old and new overlapping percentages
should be comparable; otherwise, the new overlapping percent-
ages would be lower. In this way, we avoided using the specific
genes but used the entire information of the top modules, since as
shown above, only the latter is non-randomly associated with
tumor recurrence. We also avoided the problematic step of fitting
training tumor data to an arbitrary statistical function. Instead, the
overlapping percentages of top modules were used which we
showed should be of sufficient discriminative power. More details
can be found in METHODS AND MATERIALS section and
Figure 5. In the following, we demonstrated the evaluation of this
method in three independent datasets and compared its
performance with that of previous methods using the same
datasets.
Leave one out validation. We first evaluated the
performance of our prediction method by Leave-One-Out
validation, which is a popular choice used in previous studies.
We reported the results of accuracy (the true positive rate at the
point nearest to point (0,1) of the ROC), sensitivity, specificity and
AUC to compare with existing multi-gene classifiers (Figure 6, the
detailed information in Table S3). For German dataset, our
method achieved higher performance than the recent two
methods, an accuracy of 76%, about 5–7% higher (Lin07: 71%;
Garman08: 69%), a sensitivity of 65%, about 3–24% higher
(Lin07: 62%; Garman08: 41%), and a specificity of 93%, about
Figure 3. The enrichment levels of somatic mutations in top
50–500 modules inferred from the German datasets. By contrast,
the controls are from the t-test gene and permutation test. T-test gene
analysis was performed by using the same number of top differentially
expressed genes as the number of genes covered by the corresponding
top N modules.
doi:10.1371/journal.pone.0033653.g003
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dataset, our method achieved an accuracy of 74%, a sensitivity
of 72%, a specificity of 84%, which is slightly less than the
Barrier06 results (accuracy: 80%; sensitivity: 75%; specificity:
85%) using this dataset and the resulting Barrier06 signatures. But
it is much higher than another result using the same dataset and
another Wang04 signature (accuracy: 67%). For GSE5206 dataset
that has no specific follow up time, our method achieved the lowest
but still reasonable accuracy (68%). It is also much lower than the
accuracies achieved by the original methods invented using this
dataset (90%; Garman08 method). However, we noted that this
Garman08 method, when applied to a different dataset (German
dataset), only achieved 69% accuracy. The about 21% difference
of Garman08 method in different datasets may suggest a potential
over-fitting problem of its classifier or an undesirably high
variability in its performance. In contrast, our methods had
much smaller variability (8% difference), with 74–76% accuracy
for early stage (I or II) tumors in Barrier and German datasets, and
68% accuracy for stage I–IV tumors in GSE5206 dataset. The
corresponding AUC values of our method were also similar across
all three datasets: German - 79%, Barrier - 79% and GSE5206 -
70%.
To verify the samples size’s impact on the prediction methods,
smaller samples size at 34, 18, 10 have been carried out. The
average value and the range (the minimum and maximum value)
of accuracy, sensitivity, specificity and AUC are reported in each
case (Figure 6, the detailed information in Table S3, and ROC
curve in Figure S3).
Validation with 34 training samples. We randomly picked
up n samples from each dataset, where n=34, as training set to
predict the recurrence risk for the rest tumors. For the German
and Barrier datasets, the performances are much higher than the
results in LOO validation. In detail, for German dataset, our
method achieved an accuracy of 78%, AUC of 80%, a sensitivity
of 80%, and a specificity of 76%. For Barrier datasets, it achieved
higher accuracy of 81% and specificity of 86%, and less sensitivity
of 78% than other methods (using Barrier signature: accuracy:
80%; sensitivity: 91%; specificity: 72%; using Wang04 signature:
accuracy: 70%). In addition, our method only had much less
variability (13% for Barrier dataset) than that of Barrier06 method
(31%). For GSE5206 datasets, the performance is similar with the
LOO validation, an accuracy of 70%, AUC of 66%, a sensitivity
of 74% and a specificity of 68%.
Validation with 18 or 10 training samples. Next, we
continued to decreased the size of the training set, n=18 or 10, to
validate the predict performance on the recurrence risk for the rest
tumors.. In the case of n=18, for German dataset, our method
achieved an average accuracy of 72% for German dataset, better
than all previous methods. For Barrier dataset, our method
Figure 4. The percentage of overlapping genes in top 100–1000 modules identified from two independent datasets, German and
Barrier. The overlapping percentage is calculated as the ratio for the number of intersection and union of the genes. We compared the percentage
of overlapping genes on top ranked N modules, top t test genes with the same number of genes in top N modules, and their corresponding
permutation test controls.
doi:10.1371/journal.pone.0033653.g004
Figure 5. Schematic overview of classification and evaluation.
The training tumor sets are first sampled randomly from the whole
tumor datasets and then split randomly into two equal parts, each part
including the non-recurrent and recurrent sets. Their corresponding top
modules were inferred by the approach mentioned above and the
overlapping percentage (OP_old) was calculated. For each test tumor X,
we put it into the recurrent sets for both parts to constitute the new
expression matrixes. The most differentially expressed modules for two
new expression matrixes are inferred respectively. The overlapping
percentage (OP_new) of these two sets of top modules is calculated
and normalized by the OP_old. Considering the bias from the splitting
at the step 2, the random splits were repeated for 10 times. The average
of normalized OP is assigned to test tumor X.
doi:10.1371/journal.pone.0033653.g005
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which are lower than the original Barrier06 signatures (74%), but
similar as the Wang04 signatures (65%) and a higher specificity of
71% (Barrier06: 67%). We noted that, by sampling different sets of
training tumors, our method had about half variability (13% for
Barrier dataset) than that of Barrier06 method (26%). Lastly, our
method had an average accuracy of 66% for the GSE5206 dataset,
comparable to that of Barrier (72%) and German datasets (66%).
The AUC quantities, sensitivity and specificity for all three
datasets are consistent, too: accuracy: German - 73%, Barrier -
67% and GSE5206 - 75%; sensitivity: German – 71%, Barrier –
62%, and GSE5206 – 63%; specificity: German – 73%, Barrier –
71%, and GSE5206 – 67%.
In the case of n=10, our method achieved an average accuracy
of 69%, 71% and 74%, sensitivity of 67%, 73%, and 66%,
specificity of 71%, 67%, 69% and the AUC of 68%, 68% and
63% for German, Barrier and GSE5206 datasets, respectively.
Furthermore for Barrier datasets, our methods has a higher
accuracy of 71% (using Barrier06 signatures: 66%, Wang04
signatures: 63%), and higher specificity of 67% (Barrier06:
57%).These results suggest our prediction can achieve highly
reproducible and reasonable performance across different datasets,
even with as few as 10 training tumors.
Discussion
Tumor recurrence is associated with changes in different
pathways. Such changes may be manifested in different genes
for different patients. The existing signature genes were identified
based on expression changes at individual gene levels, and thus
may not necessarily capture such pathway level changes. Here we
tackled this issue by constructing a classifier based on most
differentially expressed multi-gene modules.
Many reported classifier with higher accuracy dependent
tremendously on the training samples, indicated these classifier best
fit the existing sample instead of the whole population of the
interested phenotype. In this study we verified not only non-random
biological qualitative association between top ranked modules with
colorectal cancer recurrence in different datasets, but also higher
quantitative overlapping measure of the modules from different
datasets than random. Thus the overlapping percentage of the
modules is used to be prognosis function to avoid arbitrary fitting by
training data and potential over-fitting problem.
There are two things must be noted here. First, multi-gene
modules or sets can be identified in a number of alternative ways,
but they may not be informative enough to construct such a
classifier. In one earlier study, modules associated with tumor
metastasis of breast cancer were identified, but failed to find a
significant enrichment of somatic mutations [11]. In some another
studies, co-expressed gene set were found correlated with the
tumor development but their size is too large [41]. Considering the
definition of modules is still very liberal, we suggest that rigorous
test on their biological relevance must be done before using them
for constructing a classifier. Secondly, as shown in the case of
chemokine pathway, it may be hard to further find robust
signature genes to represent these signature modules. With only
the expression data, the information of the modules needs to be
exploited as much as possible. As a result, this leads to another
critical feature of our classifier, using the overlapping percentages
of modules as classifier function.
In conclusion we developed this novel module-based prognosis
classifiertopredicttheoutcomeof patients withthe colorectalcancer
after surgery and have demonstrated that it yielded reasonable and
reproducible performance across datasets with low variability. And it
can also yield the satisfactory and commendable performance even
at the case of fewer samples indicating it is cost-effective way which
required only fewer amounts of tumor materials. The performance
on the GSE5206 is relatively lower than other two datasets. No
specificfollowuptimewhich may cause wrong classified label for the
non-recurrent patients may be one of the reasons.
Furthermore compared with current prediction based on patho-
logical staging, this prognosis classifier can help more to identify
patients with higher recurrent risk and suggest better decisions of
personalized treatment therapy. In future clinical application, the
methods need to set several reference samples as the benchmark. For
each test patient, we compared its gene expression profile with
benchmark sets, and get the score based on our algorithm. The
patients with higher overlapping score are the higher risk ones and
should be received more intensive follow-up adjuvant therapy,
whereas the patients with lower overlapping score are the lower risk
ones and might be exonerated from the injury caused by more
aggressive treatment. The module-based prognosis strategy also brings
about a wider application in the other cancer types or other aspects,
such as evaluating responsiveness of new drug or therapeutics.
For most existing methods, it requires huge number of samples to
establish the diagnostic setting, which is usually costly and time
consuming. However, with our method, only few samplesare needed.
Furthermore in our study, a wide range of the samples size (10, 18,
34, and n-1 (n: all samples), German: 55, Barrier: 50, GSE5206: 63)
has been validated on our method, and yielded robust results to the
sample size change, that is, our method’s result will not be strongly
affected by the sample size, thus gaining a unique advantage when
applied to new region, new population and especially used in some
new discover/rare cancers. Additional information, e.g. gene copy
number variations, epigenetic data, may be helpful to further reduce
the dimension of this classifier to the gene level. In future, alternative
designs may be exploited to represent the module information and do
not rely on reference set of tumors.
Supporting Information
Figure S1 The percentage of known colorectal cancer
(CRC) genes in top 50–500 MDMs inferred from Barrier
dataset. Known CRC genes were collected from the PubGene
(A) or OMIM (B). The percentages were compared with those in
top differentially expressed genes (t-test genes) with the same
number of genes in top ranked N modules, or GO gene sets with
the same amount of top ranked N modules.
(TIF)
Figure S2 The enrichment levels of somatic mutations
in top 50–500 most differentially expressed modules(top
Figure 6. The prognosis prediction performance. The comparison of AUC (A) and accuracy (B) for three datasets: Different coloring schemes
and shape indicate three independent datasets (orange circle: German dataset; blue diamond: Barrier dataset; green square: GSE5206 dataset). TX_Y
methods (X: top 500 or 1000 MDMs; Y: 10 or 18 reference tumors or Leave-One-Out method (LOO)). The filled symbols denote the mean of AUCs; The
comparison of accuracies(C), sensitivities (D) and specificities (E) for prognosis prediction between our method and present methods with same
datasets, including the LOO results from Lin07 (L) [3], Garman08 (G) [42], Barrier06 (B) [5], and also the Barrier06’s results obtained using 34 tumors
(TS34), 18 tumors (TS18) or 10 tumors(TS 10) as the training set. The filled symbols are mean value. *The points in the dotted circle are the outcomes
from the methods which were validated using makers discovered by the one and the same dataset.
doi:10.1371/journal.pone.0033653.g006
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tially expressed genes by t-test (top t-test genes) (light
blue and dark blue) without and with permutated
‘recurrent’ and ‘non-recurrent’ labels, respectively,
identified from Barrier dataset.
(TIF)
Figure S3 ROC curve of three independent datasets
using 34(A: Top500, B: Top1000), 18 (C: Top500; D:
Top1000), or 10 (E: Top500; F: Top1000) training
samples (orange: German dataset; blue: Barrier data-
set; black: GSE5206 dataset).
(TIF)
Table S1 The number of genes and maximum p value in
Top N modules.
(DOC)
Table S2 Member genes of chemokine signaling path-
way present in top 100 modules.
(DOC)
Table S3 The comparison of classification performance
between our module-based method and other recent
methods.
(DOC)
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